Quick Answer
Tarsus Pharmaceuticals, Inc. reported Long Term Debt of $72.44 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +0.8% in Long Term Debt from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $19.18 million | Q2 2022: $19.26 million | Q3 2022: $19.36 million | Q1 2023: $24.52 million | Q2 2023: $24.61 million | Q3 2023: $29.71 million | Q1 2024: $29.93 million | Q2 2024: $71.58 million | Q3 2024: $71.71 million | Q1 2025: $71.98 million | Q2 2025: $72.13 million | Q3 2025: $72.28 million.
- Historical annual values: Fiscal year 2025: $72.44 million | Fiscal year 2024: $71.85 million | Fiscal year 2023: $29.82 million | Fiscal year 2022: $19.43 million | Fiscal year 2021: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: